Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
55 Leser
Artikel bewerten:
(0)

Global Intra-uterine Contraceptive Devices (IUCD) Market, 2017-2024 - Increasing Demand for Generic and Biosimilar Drugs

DUBLIN, October 20, 2017 /PRNewswire/ --

The "Global IUCD Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024" report has been added to Research and Markets' offering.

Research and Markets Logo

In this region, global intra-uterine contraceptive devices market is projected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024.

The global intra-uterine contraceptive devices market is segmented on the basis of product type, end user, and geography.

The global intra-uterine contraceptive devices market is segmented into 2 product types, namely copper IUCD and hormonal IUCD.

On the basis of end users the market is segmented into hospitals, gynaecology clinics, and community healthcare. In 2017, the hospital segment is expected to dominate the market and is expected to continue this trend till 2024.

Market Overview

Drivers

  • Rising Cases of Chronic Diseases
  • Rising Demand of Self-Injection Devices
  • Growth of Biologics Market
  • Technological Advancements and Innovations in Drug Delivery Market

Restraints

  • Needlestick Injuries and Infections
  • High Cost of Development
  • Strict Regulatory Framework

Opportunity

  • Increasing Demand for Generic and Biosimilar Drugs
  • Generics
  • Biosimilars
  • Increasing Demand for Contraceptive Injectables
  • Increasing Demand for Self-Administration of Drugs

Challenges

  • Alternative Route of Drug Administration
  • Product Recall
  • Stability of Products
  • Sterility of Injections

Global intra-uterine contraceptive devices (IUCD) market competition by top players including:

Bayer AG dominated the IUCD market accounting largest market share followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V. along with others such as include:

  • DKT International
  • Egemen International
  • Melbea AG
  • Ocon Medical Ltd.
  • Pregna International Limited
  • Medical Engineering Corporation SA
  • SMB Corporation and Meril Life Sciences Pvt. Ltd.
  • Medu Scientific Ltd, China RH Contraceptives Co., Ltd
  • Sanghai Jolly Medical Education Co., Ltd
  • Bernstein Leibhard LLP
  • Zheijang Daji Medical Instruments, Ltd.
  • Nimble International
  • AME Line, Technico
  • Cepeo
  • Contraceptivos
  • Injeflex Ind And Com Ltda
  • Bersil
  • Amed.

Key Topics Covered:

1. Introduction

2. Market Segmentation

3. Market Overview

4. Executive Summary

5. Premium Insights

6. Global Injectable Drug Delivery Market, Regulatory

7. Global Injectable Drug Delivery Market, by Type

8. Global Injectable Drug Delivery Market, by Application

9. Global Injectable Drug Delivery Market, by Usage Pattern

10. Global Injectable Drug Delivery Market, by Mode of Administration

11. Global Injectable Drug Delivery Market, by End User

12. Global Injectable Drug Delivery Market, by Distribution Channel

13. Global Injectable Drug Delivery Market, by Geography

14. Global Injectable Drug Delivery Market, Company Share

15. Company Profiles

  • AME Line, Technico
  • Amed.
  • Bayer AG
  • Bernstein Leibhard LLP
  • Bersil
  • Cepeo
  • Contraceptivos
  • Egemen International
  • Injeflex Ind And Com Ltda
  • KT International
  • Medical Engineering Corporation SA
  • Medu Scientific Ltd, China RH Contraceptives Co., Ltd
  • Melbea AG
  • Mona Lisa N.V.
  • Nimble International
  • Ocon Medical Ltd.
  • Pregna International Limited
  • Sanghai Jolly Medical Education Co., Ltd
  • SMB Corporation and Meril Life Sciences Pvt. Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Zheijang Daji Medical Instruments, Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/v5l825/global_iucd

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.